TS

TARGET Annual Report 2023

Retrieved on: 
星期三, 六月 12, 2024
Transfer, Nature, ISO 9362, Cost sharing, PACS, Inst, MCAS, Credit transfer, CPA, DCAS, State, ECB, European, EAT, Traction, DKK, ACHS, EPC, EURO1, A2A, RTS, Regulation, GDP, Test management, Data, Sveriges Riksbank, NRO, Risk management, TS, European Economic Area, Annual report, DWH, Central bank, Guideline, UHB, Comparison, Business, MCA, European Central Bank, Recurrence, CBT, RIX, Classification, DCA, Rural sociology, BILL, Documentation, Interbank, Amortization, Policy, Danmarks Nationalbank, ECMS, SCT, CLM, PDF, COVID-19, GUI, CLS, Website, UDFS, Leg, Information services, Risk, ACH, BICS, CAMT, TSRC, BIC, Letter, Single Euro Payments Area, Software, Credit, ISO, Running, Directory, G20, Methodology, Reproduction, MIB, APP, ASTA, Data warehouse, CMB, Environment, Incidents, LEA, ISSN, Norges Bank, Statistics, BDM, Hand, Whit, Exercise, Medical imaging

It has pioneered cross-sectoral legislation on artificial intelligence, cloud computing services and crypto-assets for this purpose.

Key Points: 
  • It has pioneered cross-sectoral legislation on artificial intelligence, cloud computing services and crypto-assets for this purpose.
  • This paper discusses digital innovation in the banking sector in the context of the academic literature on financial innovation and non-banks.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Retrieved on: 
星期五, 四月 26, 2024
Cancer, Safety, Regenerative medicine, TS, Metastasis, Trial of the century, Doctor of Philosophy, Development, Disease, CIRM, Autoimmune disease, Kite Pharma, Research and development, Patient, RCC, CD70, AACR, Clinical trial, Kidney cancer, Therapy, SAN, Pharmaceutical industry

It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.

Key Points: 
  • It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.
  • The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
  • Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2 regimen.
  • A more comprehensive data update from the ongoing trial is planned for later in 2024.

TS Conductor Wins 2024 BloombergNEF Pioneers Award for High-performance Conductor Accelerating the Energy Transition and Grid Modernization

Retrieved on: 
星期三, 四月 10, 2024
Basin Electric Power Cooperative, Breakthrough Energy, APS, Climate change, Arizona Public Service, Agriculture, BNEF, Weather, Salt River Project, Heel, TS, Congestion, ACSR, Innovation, Electricity, Research, Transport, Carbon, NextEra Energy, EV, Public utility, SRP, TVA, Bloomberg L.P., Tennessee Valley Authority, MDU, Longevity, Pioneer, Renewable energy

HUNTINGTON BEACH, Calif., April 10, 2024 /PRNewswire-PRWeb/ -- TS Conductor (TS), a leader in providing high-performance transmission and distribution conductors for electricity grids, today announced it has been named a winner of the 2024 BloombergNEF (BNEF) Pioneers Award. BNEF recognized TS for the ability of its advanced conductor solution to relieve bottlenecks in the deployment of clean power — one of the three challenges BNEF assessed for this year's Pioneers award program.

Key Points: 
  • HUNTINGTON BEACH, Calif., April 10, 2024 /PRNewswire-PRWeb/ -- TS Conductor (TS), a leader in providing high-performance transmission and distribution conductors for electricity grids, today announced it has been named a winner of the 2024 BloombergNEF (BNEF) Pioneers Award.
  • "It is an incredible honor to receive this prestigious award from BNEF, and our team is very grateful," said Dr. Jason Huang, CEO of TS Conductor.
  • TS is backed by investors such as Breakthrough Energy Ventures, National Grid Partners, NextEra Energy, and others.
  • Many past BNEF Pioneers winners have gone on to become major players in the global energy transition solution space.

Neupulse Secures Funding to Advance World’s First Wearable Device to Tackle Tourettes Syndrome

Retrieved on: 
星期一, 三月 18, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Biotechnology, Hardware, Health, General Health, Tic, University, Education, TS, Eos, Tourette syndrome, Quality of life, Pain, Median nerve, Multimedia, Wrist, Work, Social integration, Pharmaceutical industry

Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.

Key Points: 
  • Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.
  • Clinical trials in 2023 showed the Neupulse device can reduce tics by over 25 percentile.
  • Tourettes Syndrome is a neurological condition characterized by involuntary, repetitive movements and vocalizations known as tics.
  • Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy.

Rittal Announces Colocation Rack Initiative to Meet the Growing Demand for Colocation Market

Retrieved on: 
星期五, 三月 1, 2024
Marketing, Rittal, MDC, TS, Micro data center

SCHAUMBURG, Ill., March 1, 2024 /PRNewswire/ -- Rittal LLC, a leader in providing infrastructure solutions for IT applications, launches its new line of enclosures designed for the colocation market.

Key Points: 
  • SCHAUMBURG, Ill., March 1, 2024 /PRNewswire/ -- Rittal LLC, a leader in providing infrastructure solutions for IT applications, launches its new line of enclosures designed for the colocation market.
  • Developed based on key feedback, the new initiative will accelerate and grow the success of all parties involved in the colocation market with comprehensive education, sales support, and marketing resources.
  • Cassiano Fabris, Vice President of Global Key Accounts for Rittal, stated how the colocation market is evolving, saying, "The colocation market is continuously growing at impressive speeds.
  • The TS IT Colo ensures that data centers not only meet the requirements of colocation operators, but also cover the essential needs of the market and remain fit for the future.

ICE Bonds Broadens Its Fixed Income Liquidity Network with Connectivity to TS Imagine

Retrieved on: 
星期一, 二月 5, 2024
Technology, Finance, Fintech, Banking, Professional Services, Software, Data Analytics, Asset Management, Data Management, Intercontinental, Intercontinental Exchange, Municipal bond, TS, ICE, RFQ, Security (finance)

Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of technology and data, today announced that TS Imagine has connected to ICE Bonds to offer clients seamless access to its fixed income execution protocols and liquidity.

Key Points: 
  • Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of technology and data, today announced that TS Imagine has connected to ICE Bonds to offer clients seamless access to its fixed income execution protocols and liquidity.
  • TS Imagine customers using the TS One and TradeSmart OEMS can now access ICE Bonds’ trading protocols for Municipals and Corporates, across the ICE TMC and ICE BondPoint platforms.
  • “TS Imagine’s cross-asset platform has become a leading tool for investors around the world and we’re pleased to be delivering ICE Bonds’ streaming municipal and corporate bond data and liquidity to their customers,” said Peter Borstelmann, President of ICE Bonds.
  • By electing to use the ICE Bonds API for connectivity, TS Imagine’s customers will have access to diverse pools of fixed income liquidity via the ICE Bonds’ suite of trading protocols, including click-to-trade and request-for-quote (RFQ).

2seventy bio Announces New Strategic Path Forward

Retrieved on: 
星期二, 一月 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Partnership, ODAC, Multiple myeloma, Growth, Bristol Myers Squibb, CMO, Science, Research, Trial of the century, GV (company), Patient, AML, BMS, BCMA, LVV, Ovarian cancer, MUC16, Physician, Autoimmunity, APA, TS, PDUFA, Webcast, Workforce, Johnson & Johnson, Management

2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.

Key Points: 
  • 2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.
  • 2seventy bio and BMS are expanding its Abecma site footprint to enable more patients to access the treatment.
  • Upon closing of the transaction with Regeneron, Chip Baird, chief operating officer, will become chief executive officer of 2seventy bio.
  • After 13 years of service on the bluebird bio and 2seventy bio Board of Directors, Dan Lynch will step down from the Board in June and will continue in an advisory role for 2seventy bio.

David Werner Real Estate Investments Secures Long-term Lease Extension with Dow at Collegeville, Pennsylvania Life Sciences Campus

Retrieved on: 
星期二, 一月 16, 2024
TS, Research, Science, History, Medicine, Tenant, Personal care, Pleasure, Growth, Commercial property

NEW YORK and MORRISTOWN, N.J., Jan. 16, 2024 /PRNewswire/ -- David Werner Real Estate Investments (DWREI) today announced the signing of a long-term lease extension with Dow, a global materials science company, at its life sciences and office campus in Collegeville, Pa. Dow, whom Newmark Group represents, has agreed to an extension of its lease term for approximately 800,000 square feet that includes the company's Northeast Dow Center, a significant research and development center for the company. 

Key Points: 
  • NEW YORK and MORRISTOWN, N.J., Jan. 16, 2024 /PRNewswire/ -- David Werner Real Estate Investments (DWREI) today announced the signing of a long-term lease extension with Dow , a global materials science company, at its life sciences and office campus in Collegeville, Pa. Dow, whom Newmark Group represents, has agreed to an extension of its lease term for approximately 800,000 square feet that includes the company's Northeast Dow Center, a significant research and development center for the company.
  • DWREI and its partner GreenBarn Investment Group completed the purchase of the campus this past August from Pfizer Inc., who remains a tenant at the property.
  • Spanning approximately 1.9 million square feet and located just 22 miles northwest of Downtown Philadelphia, the campus includes 14 interconnected office, life science and mixed-use office buildings across 340 acres.
  • We look forward to continuing to serve Dow and Pfizer, a blue-chip organization with a 170-year history centered on innovation in science, medicine and healthcare."

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Retrieved on: 
星期四, 一月 4, 2024
PIN, TS, EFS, Kite Pharma, Cancer, Conference, B-cell lymphoma, Disease, Steroid, CLL, Lymphocyte, First Line, CRS, Safety, News, Patient, Cyclophosphamide, MRD, AID, Cytokine release syndrome, Therapy, CF1, CD70, Biology, Westin St. Francis, Autoimmune disease, Renal cell carcinoma, SAN, Standard of care, Demand, Observation, RCC, CD19, Vaccine

“Until now, CAR T development has been defined by how autologous CAR Ts are made and used.

Key Points: 
  • “Until now, CAR T development has been defined by how autologous CAR Ts are made and used.
  • The standard of care after 1L treatment has been simply to “watch and wait” for the disease to relapse.
  • ALPHA3 builds on the growing understanding that administration of CAR T therapies to patients with low disease burden improves both safety and efficacy outcomes.
  • The 2024 Platform Vision Conference Call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.

Knightscope Authorized Partner TS&L Purchases First 13 K1 Blue E-Phones for Georgia State University

Retrieved on: 
星期二, 一月 2, 2024
Public Policy, Government, Telecommunications, Software, Robotics, Public Safety, Technology, Mobile, Wireless, Security, Safety, Security Division (Wehrmacht), Knightscope, Georgia State University, TS, Transport, Mobile phone

Knightscope, Inc. [Nasdaq: KSCP] (“Knightscope” or the “Company”), a leading developer of autonomous security robots and blue light emergency communication systems, today announces its first order of 13 K1 Blue Light E-Phones for Georgia State University (“GSU”) by Knightscope Authorized Partner (“KAP”) Transportation Solutions & Lighting, Inc., – Safety and Security Division – National Safety Systems (“NSS/TS&L”).

Key Points: 
  • Knightscope, Inc. [Nasdaq: KSCP] (“Knightscope” or the “Company”), a leading developer of autonomous security robots and blue light emergency communication systems, today announces its first order of 13 K1 Blue Light E-Phones for Georgia State University (“GSU”) by Knightscope Authorized Partner (“KAP”) Transportation Solutions & Lighting, Inc., – Safety and Security Division – National Safety Systems (“NSS/TS&L”).
  • As announced in July 2023 , this is the first of what is ultimately expected to be more than 50 emergency communication devices to be installed at the downtown Atlanta campus by TS&L.
  • View the full release here: https://www.businesswire.com/news/home/20240102788571/en/
    Knightscope Authorized Partner TS&L Purchases First 13 K1 Blue E-Phones for Georgia State University (Photo: Business Wire)
    The bright blue lights on Knightscope's K1 emergency phones lead those in need to fixed locations for accessing dependable communications away from buildings, when a cellphone battery dies, or there is simply no service available.
  • At the push of a button, a student, guest or teacher may call security for immediate assistance in the event of an emergency.